Anxiety in gynecology: three clinical cases
https://doi.org/10.21518/2079-701X-2019-13-172-177
Abstract
Tofisopam is an anxiolytic drug, available for prescription by gynecologist. This paper discusses three typical case vignettes, where woman’s anxiety interfered with her somatic condition and responded on tofisopam. There is also a discussion of combination of tofisopam with hormonal therapy and it’s efficacy and safety.
About the Authors
D. I. Burchakov
Higher Medical School
Russian Federation
Russian Federation
Denis I. Burchakov, Associate Professor, Chair for Endocrinology, Non-State Educational Private Institution of Continuing Professional Education «Higher Medical School»
Office 410, 3A/2 Malaya Semenovskaya Street, Moscow, 107023
R. A. Chilova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Raisa A. Chilova, Dr. of Sci. (Med.), Professor, Chair for Obstetrics and Gynecology
8, p. 2, Trubetskaya Street, Moscow, 119991
References
1. Diukova G.M., Saksonova E.V., Golubev V.L. Grandaxin in neurological practice. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2009;(9):44–48. (In Russ.) Available at: https://elibrary.ru/item.asp?id=13123955.
2. O’Brien P.M., Backstrom T., Brown C., Dennerstein L., Endicott J., Epperson C.N., Eriksson E., Freeman E., Halbreich U., Ismail K.M., Panay N., Pearlstein T., Rapkin A., Reid R., Schmidt P., Steiner M., Studd J., Yonkers K.Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14(1):13-21. doi: 10.1007/s00737-010-0201-3.
3. Foster R.,•Vaisberg M., Bachi A.L.L., dos Santos J.d.M.B., de Paula Vieira R., LunaJunior L.A.,•Araujo M.P., Parmigiano T.R., Borges F., Di-Bella Z.I.K.J. Premenstrual Syndrome, Inflammatory Status, and Mood States in Soccer Players. Neuroimmunomodulation. 2019;26:1–6. https://doi.org/10.1159/000494559
4. Jung S.J., Roberts A.L., Chocano-Bedoya P., Whitcomb B.W., Missmer S.A., Manson J.E., Hankinson S.E., Bertone-Johnson E.R., Koenen K.C. Posttraumatic stress disorder and development of premenstrual syndrome in a longitudinal cohort of women. Archives of Women s Mental Health. 2018;22(9). doi: 10.1007/s00737-018-0916-0.
5. Arslantaş H., Abacigil F., Cinakli Ş. Relationship between premenstrual syndrome and basic personality traits: a cross-sectional study. Turkey Sao Paulo Med J. Original article. 2018;136(4):339–345. doi: 10.1590/15163180.2018.0061240418.
6. Bertone-Johnson E.R., Whitcomb B.W., Rich-Edwards J.W., Hankinson S.E., Manson J.E. Premenstrual Syndrome and Subsequent Risk of Hypertension in a Prospective Study. Am J Epidemiol. 201 Dec 15;182(12):1000-9. doi: 10.1093/aje/kwv159.
7. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;(2):CD006586. doi: 10.1002/14651858.CD006586.pub4.
8. Praharaj S.K., Arora M., Sarkhel S. Sensory disturbances associated with serotonin reuptake inhibitors: brief review. Human Psychopharmacology. 2010;25(3):216–221. doi: 10.1002/hup.1109.
9. Howard L.M., Molyneaux E., Dennis C.-L., Rochat T., Stein A., Milgrom J. Non-psychotic mental disorders in the perinatal period. The Lancet. 2014;384:1775-1788. doi: 10.1016/S0140-6736(14)61276-9.
10. Stewart D.E., Vigod S.N. Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. Annual Review of Medicine. 2019;70:183–196. doi: 10.1146/annurev-med-041217-011106.
11. Dale-Hewitt V., Slade P., Wright I. et al. Patterns of attention and experiences of post-traumatic stress symptoms following childbirth: an experimental study. Arch Womens Ment Health. 2012;15(4):289-296. doi: 10.1007/s00737-012-0290-2.
12. Stewart D.E., Vigod S. Postpartum depression. N Engl J Med. 2016;375(22):2177–2186. doi: 10.1056/NEJMcp1607649.
13. Sober S., Schreiber C.A. Postpartum contraception. Clin Obstet Gynecol. 2014;57(4):763-76. doi: 10.1097/GRF.0000000000000055.
14. Bromberger J.T., Kravitz H.M., Chang Y., Randolph J.F., Avis N.E., Gold E.B., Matthews K.A. Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation. Menopause. 2013;20(5):488-495. doi: 10.1097/gme.0b013e3182730599.
15. Siegel A.M., Mathews S.B. Diagnosis and Treatment of Anxiety in the Aging Woman. Curr. Psychiatry Rep. 2015;17:93. doi: 10.1007/s11920-015-0636-3.
16. Bonnet N., Bernard P., Beaupied H., Bizot J.C., Trovero F., Courteix D.; Benhamou C.L. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol Appl Pharmacol. 2007;221(1):111-118. doi: 10.1016/j.taap.2007.02.005.
Review
For citations:
Burchakov DI, Chilova RA. Anxiety in gynecology: three clinical cases. Meditsinskiy sovet = Medical Council. 2019;(13):172-177. (In Russ.) https://doi.org/10.21518/2079-701X-2019-13-172-177
Views:
918
Email this article 